莫西沙星与头孢他啶联合阿奇霉素治疗重症社区获得性肺炎疗效对比观察

Moxifloxacin and ceftazidime combined with azithromycin treatment of severe community acquired pneumonia observation on the effects

目的评价莫西沙星的临床疗效及安全性。方法将2008年5月至2010年5月辽宁医学院附属第一医院呼吸科收治的80例确诊为重症社区获得性肺炎患者随机分为两组,莫西沙星组40例,对照组为头孢他啶联合阿奇霉素治疗组40例,观察两组疗效。结果莫西沙星组治疗重症CAP的有效率为95%,细菌清除率为85.71%,不良反应发生率为5%,均明显优于对照组(P<0.05)。在显效时间及对支原体疗效方面亦优于对照组。结论莫西沙星治疗CAP效果满意,不良反应少,是治疗CAP安全、有效的抗菌药物。

Objective Azithromycin combined with ceftazidime in the treatment of severe community-acquired pneumonia（CAP） were compared to evaluate the clinical efficacy and safety of moxifloxacin. Methods 80 cases diagnosed as severe community acquired pneumonia were randomly divided into two groups ,40 cases of mox- ifloxacin group and control group ceftazidime combined with azithromycin group, curative effect was observed. Resuits Moxifloxacin treatment of severe CAP in the effective rate was 95%, the bacterial clearance rate was 85.71% ,the adverse reaction rate of 5% ,were significantly better than the control group was statistically signifi- cant. Time and in the markedly effective efficacy against Mycoplasma is also better than the control group. Conclu- sion The effect of moxifloxacin in treatment of CAP satisfied with less adverse reactions, treatment of CAP is safe and effective antimicrobial agents.